Jack Stahl - Catalent Lead Independent Director
Director
Mr. Jack L. Stahl is Lead Independent Director of the Company. Mr. Stahl was the President and Chief Executive Officer of Revlon, Inc. from 2002 until his retirement in 2006. Prior to joining Revlon, Mr. Stahl served as President and Chief Operating Officer of The CocaCola Company from 2000 to 2001, having previously served in various management positions since joining the company in 1979. Mr. Stahl serves on the board of Advantage Solutions LLC and on the U.S. board of advisors of CVC Capital. Additionally, Mr. Stahl formerly served on the boards of ScheringPlough Corporationrationration, Dr Pepper Snapple Group, Saks, Inc., Coty Inc., and Royal Ahold Delhaize, and was chairman of the board of managers of New Avon LLC since 2016.
| Age | 67 |
| Tenure | 9 years |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Jack Stahl Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jack Stahl against Catalent stock is an integral part of due diligence when investing in Catalent. Jack Stahl insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jack Stahl over three months ago Acquisition by Jack Stahl of 4663 shares of Catalent subject to Rule 16b-3 | ||
Jack Stahl over six months ago Acquisition by Jack Stahl of 6993 shares of Catalent subject to Rule 16b-3 | ||
Jack Stahl over a year ago Acquisition by Jack Stahl of 6993 shares of Catalent subject to Rule 16b-3 |
Catalent Management Efficiency
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paolo Pucci | West Pharmaceutical Services | 59 | |
| John Danhakl | IQVIA Holdings | 64 | |
| Arnold Pinkston | Bio Rad Laboratories | 62 | |
| William Feehery | West Pharmaceutical Services | 50 | |
| Myla LaiGoldman | West Pharmaceutical Services | 62 | |
| Thomas Hofmann | West Pharmaceutical Services | 68 | |
| James Fasano | IQVIA Holdings | 50 | |
| Virginia Wilson | Charles River Laboratories | 66 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| Deborah Tanner | West Pharmaceutical Services | 57 | |
| John Leonard | IQVIA Holdings | 62 | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| Richard Wallman | Charles River Laboratories | 69 | |
| Martin Mackay | Charles River Laboratories | 65 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Gregory Hinckley | Bio Rad Laboratories | 74 | |
| Jeffrey Edwards | Bio Rad Laboratories | 60 | |
| Tania DeVilliers | Bio Rad Laboratories | 51 | |
| Colleen Goggins | IQVIA Holdings | 66 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Stephen Chubb | Charles River Laboratories | 76 | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 16.13 B | |||
| Shares Outstanding | 181.51 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 14.74 M | |||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |